Trial Profile

Global Study to Investigate Safety and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 08 Jul 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Donanemab (Primary)
Indications Alzheimer's disease
Focus Registrational; Therapeutic Use
Acronyms TRAILBLAZER-ALZ 5
Sponsors Eli Lilly and Company

Most Recent Events

11 Jun 2025 Planned End Date changed from 1 Apr 2027 to 1 Jul 2028.
11 Jun 2025 Planned primary completion date changed from 1 Apr 2027 to 1 May 2028.
09 Dec 2024 Planned End Date changed from 30 Apr 2027 to 1 Apr 2027.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com